Markets
MARKETSTHE EPINEX G1A™ TEST: MARKETS OVERVIEW
Strategy: Create a paradigm shift in the diabetes monitoring market based on monthly consultation and testing for most Type 2 diabetics
Goal: Make the Epinex G1A™ Test a standard practice for monitoring short-term glycation
| THE PROBLEM | THE SOLUTION |
| The current diabetes monitoring paradigm is not working | Monthly consultation and testing using the G1A™ test |
| Inaccurate for many diabetics | Glycated albumin is more sensitive and more accurate than existing methods |
| Inconvenient or delayed time frames | Monthly measure of direct protein damage allows for more timely treatment intervention and enhances preventive care |
| High frustration and low compliance | Monthly test frequency promotes increased patient comfort and better quality of life |
| Very expensive | G1A™ may lead to cost savings of over $1 billion per year |
Distribution Channels:
Physician’s Office Laboratory (POL)
- Doctors’ Offices
Point of Care (POC):
- Emergency Rooms
- Ambulances
- Outpatient Care Centers
- Clinics for Rapid Diagnostic Testing
- Community & Corporate Wellness Programs
Over-the-Counter (OTC)
- Home Health Care
- Pharmacies
- Corporate/Community Wellness Centers
- Screening: Workplaces, Health Fairs